Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Indigo Diabetes Starts Human Trial Of Subcutaneous Glucose Monitor

Executive Summary

The company has enrolled the first patient in the second human trial of its implantable metabolite monitoring system, which it expects could change the game for blood glucose measurement.

You may also be interested in...



Minute Insight: Nutromics Raises $14m As Dexcom Signals Move Into Wider Sensing Capabilities

Nutromics is working on a portfolio of aptamer-based sensors capable of measuring a wide range of analytes found in interstitial fluid.

Needles Are Out, Future Tech Is In, For Blood Glucose Measurement

Medtech Insight has spoken to several companies aiming to release devices that will replace current blood glucose monitors via disruptive, innovative technologies.

Minute Insight: Intel-Penn Tie-Up Proves Federated Approach’s Power

Federated learning has taken another step forward thanks to new research that proves it is better at spotting brain tumors. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel